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This focus article introduces the concept of NutriChip, an integrated microfluidic platform for investigating
the potential of the immuno-modulatory function of dairy food. The core component of the NutriChip is a
miniaturized artificial human gastrointestinal tract (GIT), which consists of a confluent layer of epithelial
cells separated from a co-culture of immune cells by a permeable membrane. This setting creates
conditions mimicking the human GIT and allows studying processes that characterize the passage of
nutrients though the human GIT, including the activation of immune cells in response to the transfer of
nutrients across the epithelial layer. The NutriChip project started by developing a biologically active in
vitro cellular system in a commercial Transwell co-culture system. This Transwell system serves as a
reference for the micro-scale device which is being developed. The microfluidic setup of NutriChip allows
monitoring of the response of immune cells to pro-inflammatory stimuli, such as lipid polysaccharide (LPS),
and to the application of potentially anti-inflammatory dairy food. This differential response will be
quantified by measuring the variation in expression of pro-inflammatory cytokines, including interleukin 1
(IL-1) and interleukin 6 (IL-6), secreted by the immune cells, and this is achieved by using a dedicated
optical imager. A series of dairy products will be screened for their anti-inflammatory properties using the
NutriChip system and, finally, the outcome of the NutriChip will be validated by a human nutrition trial.
Therefore, the NutriChip platform offers a new option to evaluate the influence of food quality on health,
by monitoring the expression of relevant immune cell biomarkers.
Milk and the modulation of the
inflammatory response
It is now generally accepted that food is not only a source of
nutrients but also a modulator of the physiological functions
of the body. The response of the body depends on the type of
diet and it is believed that each meal provokes a kind of
inflammatory response. The cellular metabolism of nutrients,
culminating in the synthesis of biochemical energy, produces
side effects that include the generation of oxidative stress.
These effects accumulate at the level of the organism to
produce a phenomenon, called postprandial stress.1 Under
normal conditions, postprandial stress is of low magnitude
and disappears within a few hours post-ingestion. An
unhealthy diet may, however, increase the magnitude of
postprandial stress and/or delay the person’s recovery to the
initial state.2 A repetition of postprandial inflammatory stress
over prolonged periods of time may significantly contribute to
the development of chronic inflammation. Therefore, the
inflammatory stress imposed by inadequate or inappropriate
diets may contribute negatively to the maintenance of health
by reducing the metabolic plasticity of the organism. A
quantitative analysis of the postprandial presence and kinetics
of inflammatory biomarkers provides information on the
quality of the interaction between specific foods and the
organism. This idea is at the conceptual basis for the
biological module of the NutriChip, as explained in ref. 3.
Milk and dairy products have long been promoted as
healthy nutrients, rich in proteins, vitamins and minerals and
providing the necessary components in the food standard
pyramid for both children and adults. Recently, milk has been
promoted as not only a nutrient source but also as a health
promoter. Indeed, milk is a source of immuno-modulatory
effects, produced through the action of probiotic bacteria,
proteins and bioactive peptides in the fermented milk
products. A potentially important action is based on modulat-
ing the production of pro-inflammatory cytokines.4 Fasting-
related lower levels of pro-inflammatory cytokines have been
documented in epidemiological5 and intervention6 studies in
human adults consuming dairy products. Decreased post-
prandial levels of pro-inflammatory cytokines after the con-
sumption of dairy products were also reported.7 Taking into
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account the vast possibilities of transformation technologies
of milk, in particular fermentation by lactic acid bacteria, and
the importance that gut microbiota have on human metabo-
lism,8 it appears that milk can be a strategic vector to deliver
immuno-modulatory nutrients for improving metabolism and
health.
Biological model
In the human body, food undergoes complex processes that
involve adsorption, distribution, metabolism, and excretion
(ADME). Nowadays, human intervention studies are clearly the
gold standard in nutritional science,8 because all factors that
influence the ADME processes are present. However, it is
impossible to identify the influence of individual factors, and
the resources necessary to screen a large number of products
for specific properties are prohibitive. Furthermore, the use of
human subjects as a screening tool to test products that are
not bio-active or even unsafe poses ethical problems, even if
the trials involve a low grade of invasiveness by limiting
analyses to blood samples. As differences between human and
animal metabolism are significant, human in vitro cell culture
models are needed for the efficient screening of bio-active food
products. Use of such models would increase the predictability
of human responses to nutrients and lead to higher success
rates in follow-up clinical studies, significantly reduce
expenses associated with the clinical studies and speed up
the screening processes.
In analogy to pharmacokinetics, the absorption of nutrients
through intestinal cells is a key factor for their bio-availability.
The mucosal surface of the intestinal tract is covered by a thin
layer of epithelial cells (ECs) underlined by a local immune
system.9 This biological construction plays a dual role: (i) it
transfers nutrients into the circulation for further metabolism,
while maintaining immune tolerance to these nutrients, and
(ii) prevents entry of pathogenic organisms into tissues and
regulates local inflammatory and immune responses to
combat such intrusions. Communication between intestinal
ECs and immune cells is thus essential, and takes place either
via soluble factors or by direct cell–cell interaction at the cross-
roads of nutrient metabolism and immuno-modulation.10,11 In
vitro intestinal nutrition transport is most often measured
using confluent layers of intestinal cell lines, and Caco-2 cells
are the most popular cellular model in transport studies. Even
though these cells are derived from a human colorectal
adenocarcinoma, they express the majority of the morpholo-
gical and functional characteristics of small intestinal absorp-
tive cells in culture.12 For example, they differentiate into
polarized intestinal cells, possessing an apical brush border
and tight junctions between adjacent cells. Therefore the core
biological component of the NutriChip is a co-culture of a
confluent layer of Caco-2 cells, which allows the application of
in vitro-digested food on its apical side, and a basolateral
culture of a monocytic cell line (in our case U937 cells)
differentiated into macrophages. The two cell types are
separated by a membrane that is permeable to the nutrients
added on the apical side of the EC culture. U937 is a histiocytic
lymphoma cell line with monoblastic characteristics and can
differentiate into macrophage-like cells after treatment with
phorbol esters, such as phorbol-12-myristate 13-acetate
(PMA).13 This co-culture setting mimics the in vivo human GIT.
Fitting the biological model into a
microfluidic setup
A microfluidic cell-based system can potentially provide a
better, faster and more efficient characterization of a
nutrients’ absorption and immuno-modulatory functions.
Considerable effort has already been made to provide in vitro
surrogates that are designed to mimic the physiological
architecture and dynamics of human organs. In particular,
we mention here the Ingber group at Harvard University,14–16
who did pioneering work on ‘‘organ-on-a-chip’’ devices and
the Shuler group at Cornell University who have pioneered the
development of in vitro analogues to physiologically-based
pharmacokinetic (PBPK) models.17–21 Such micro-scale devices
have the potential to accurately produce physiologically
realistic parameters and can closely model the desired in vivo
system to be tested. In a recent publication, Kim et al.16
reported a ‘‘human gut-on-a-chip’’ microdevice, which was
composed of a confluent layer of intestinal epithelial (Caco-2)
cells cultured on a porous membrane. The gut microenviron-
ment was mimicked by flowing fluid at a flow rate of 30 mL
h21, producing low shear stress on the cells (0.02 dyne cm2)
and by exerting cyclic strain that mimicked physiological
peristaltic motions. Under these conditions, well-defined
epithelial monolayers were formed in three days in the
microfluidic device, much faster than obtained in macroscopic
conventional cell culture devices, which require 7–21 days of
culture to achieve the same cell morphology. To study
physiologically relevant human intestinal epithelial cell
microbe interactions, the authors co-cultured a strain of
Lactobacillus rhamnosus on the luminal surface of the cultured
epithelium without compromising the epithelial cell viability,
which demonstrated the possibility of mimicking the dynamic
physical and functional features of the human intestine.
Fig. 1 illustrates schematically the biological and micro-
fluidic aspects of the NutriChip platform. The human GIT is
approximated by a monolayer of epithelial cells interacting
with immune cells (Fig. 1a). The intestinal epithelium is
considered a natural gatekeeper that controls the uptake of
nutrients and potentially harmful substances by different
passive and active mechanisms of transfer of these molecules
from the mucosal to the serosal side. The immune cell layer
underlying the epithelial barrier is highly specialized and
devoted to two main tasks, namely avoiding unnecessary and
potentially harmful reactivity to dietary proteins and enteric
flora, while rapidly responding at the same time to episodic
threats from pathogens. In a standard in vitro epithelial cell
culture system, the transport of drugs and nutrients is
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Fig. 1 The NutriChip platform concept. (a) The human GIT is approximated by a biological model consisting of a monolayer of confluent epithelial cells interacting
with immune cells. (b) First co-culture is done in a macroscopic Transwell device: a layer of confluent epithelial cells is grown on a porous membrane that forms the
bottom of an insert, which is placed inside a well containing the immune cells. (c) Schematic of the microfluidic chip forming the miniaturized GIT. (d) A top view of a
single apical fluidic chamber with small perfusion channels. (e) The miniaturized GIT inserted in a prototype microfluidic interface unit.
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measured through a confluent layer of epithelial cells.12,22 A
confluent Caco-2 cell monolayer is commonly used in studies
of the mechanism of drug transport and its absorption23 and,
similarly, such a system can be used to identify metabolite
transport originating from a variety of digested food types.24
When going for a cell co-culture model, this allows additional
measuring of the activation of immune cells in response to the
transfer and processing of nutrients across the epithelial cell
layer, and such system can therefore potentially be used to
screen food for specific physiological properties of nutrients,
in particular in the context of the immuno-modulatory
function of the latter. In a classical Transwell (Millipore,
USA) co-culture device, a layer of confluent epithelial cells is
grown on a porous membrane that forms the bottom of an
insert, which is placed inside a well containing the immune
cells (Fig. 1b). Such a system allows access to the cells from
both the apical and basolateral side. In the NutriChip project,
the co-culture system has been designed to allow measure-
ment of the differential response of immune cell stimulation
through the epithelial monolayer using two parallel co-culture
units. These units contain the same cell co-cultures and grow
under the same conditions, however, the cells in the first unit
are stimulated by a pro-inflammatory stimulus, for example
lipo polysaccharide (LPS), which is an endotoxin found in the
outer membrane of Gram-negative bacteria and is known as a
powerful activator of immune cells,25 while the cells in the
other unit are treated with digested milk and dairy products
for investigating the potential anti-inflammatory properties of
the latter.
Although such insert systems are easy to deal with and
represent a logical option for starting our research, they
require a large amount of cells, reagents and culture media,
which makes this a rather expensive approach. Furthermore,
the culture environment within these inserts does not closely
mimic the in vivo microenvironment due to the absence of the
fluid flow and shear stresses.26 Also, they are less suited to
providing a dynamically controlled flow of cell nutrients and
stimuli and, additionally, the accumulation of waste within
the insert leads to a pH drift in the static culture. Other
drawbacks of the classical cell culture systems are the long
growth times needed for the intestinal cells to differentiate
into functional enterocytes and to reach confluence, and an
external signal detection system that requires the manual
manipulation of samples. It is therefore highly desirable to
downscale such cell cultures and to make them more
amenable to automation in order to promote efficient in vitro
screening of the physiological properties of selected food
products. Microfluidic culture systems can provide the steady-
state culture conditions that mimic the in vivo fluid flow and
shear stress in a controllable manner, thus bringing the GIT in
vitro model closer to the physiological micro-environment.
Fig. 1c illustrates the structure of a basic miniaturized GIT,
which comprises two microfluidic layers made of polydi-
methylsiloxane (PDMS), which are termed here as the ‘apical’
and the ‘basolateral’ layers, respectively. These two layers
sandwich a polyester membrane with a pore size of 0.4 mm.
The apical layer contains a single chamber (Fig. 1d), which
hosts the epithelial cells and is interfaced by a chamber made
in the basolateral layer, which receives the chemicals and
nutrients transported through the epithelial confluent cell
layer grown on the membrane. It was found that the culture
conditions of the epithelial and the monocytic cells are
incompatible, therefore, a dedicated culture chamber was
created for the monocytes next to the EC basolateral chamber.
The two chambers are separated by a normally-closed valve,
which is opened for the monocyte stimulation process.
Downstream of the monocyte chamber, there is another
chamber dedicated to performing an immunomagnetic assay,
within which magnetic beads functionalized with antibodies
against the targeted cytokines dynamically capture the latter.
Utilizing magnetic beads allows in situ cytokine capturing and
simultaneous washing27 before the final fluorescent detection.
The apical and the basolateral layers were individually
molded in PDMS employing a master structure of SU-8
negative photoresist, which was previously micropatterned
on a silicon wafer. The porous membrane was obtained from a
Transwell insert. The three parts were then assembled together
by treating the three surfaces with O2 plasma in a multiple-
step bonding process. A cell culture chamber is designed to be
nested inside a larger chamber with permeable side walls
implemented by an array of small perfusion channels, which
only allows the perfusion of the chamber with media while
preventing cells to escape (Fig. 1d). Injecting the media
through these small channels allows for a uniform radial
fluid flow from all directions and uniform fluid transport over
the cells. In this way, the perfusion chamber protects cells
from elevated shear stresses and only supplies a mild shear
stress which is beneficial for the natural culture conditions.
The NutriChip is mounted in a custom-fabricated chip holder
to facilitate cell loading as well as continuous infusion of the
culture media (Fig. 1e).
First experimental results
Our first approach has been to create a biologically active in
vitro co-culture cellular system in Transwell devices. This
allowed the modeling of the GIT and it’s response to pro-
inflammatory stimuli, such as LPS by the activation of
receptors on the surface of immune cells underlying the
epithelial layer. The transport function of the epithelial layer
plays a vital role in the inflammatory response of the immune
cells. The epithelial cells are joined at their apical surface by
tight junctions (TJs), and mass transfer from the apical side to
the basolateral side of the epithelium is dependent on the
integrity of the epithelial monolayer. TJ permeability is
regulated by various factors, including bacteria toxins and
cytokines28 (Fig. 2a). Recent studies have shown that the
intestinal functions are also affected by food factors that
modulate the TJ.28,29 The integrity of the confluent epithelial
cell layer was shown by measuring the Trans Epithelial Electric
Resistance (TEER) which reached a maximal level after one
This journal is  The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 196–203 | 199
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week (Fig. 2b). Caco-2 cell differentiation was confirmed by
measuring the alkaline phosphatase (AP) activity, which is a
digestive brush-border enzyme up-regulated during small
intestinal epithelial cell differentiation; detection was done
using the AP determination kit from Roche (Roche Applied
Science, Switzerland). The assay is based on the conversion of
the substrate p-nitrophenylphosphate into phosphate and
p-nitrophenol by alkaline phosphatase. The amount of
p-nitrophenol is assessed by measuring the absorbance using
a spectrophotometer at 405 nm at the end of the reaction. In
Fig. 2 (a) Schematic of the experimental design of the GIT model, showing the cells’ co-culture and the setup for Trans Epithelial Electric Resistance (TEER)
measurements, the stimuli applied to the epithelial cell layer, and the detection biomarkers. (b) TEER measurements in a Transwell device indicate that the Caco-2 cells
form a confluent monolayer (inset) after one week of culture. (c) Alkaline phosphatase (AP) activity, i.e., the conversion of the substrate p-nitrophenylphosphate into
phosphate and p-nitrophenol, as detected by measuring the p-nitrophenol concentration, indicates correct Caco-2 cell differentiation. (d) The percentage of AP
expression with reference to day zero of the differentiation process, as measured using western blotting. (e) Caco-2 monolayer permeability to FITC-dextran,
modulated by applying LPS (1 mg mL21 [LPS(1)] and 10 mg mL21 [LPS(10)]) and TNFa, or a combination of these stimuli; UT: untreated. TNFa appears to be the
strongest permeability modulator. (f) IL-6 expression measured at the basolateral side as a response to apical stimulation with LPS and TNFa, or a combination of both
stimuli. (g) Increase of IL-6 secretion after treating differentiated monocytes (U937) with LPS, as measured using an immunomagnetic assay. Error bars indicate
standard deviations from the average of at least three measurements.
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parallel, AP expression was followed by western blotting using
a specific antibody (Sigma, Switzerland). AP activity reached
maximal levels after two weeks of differentiation (Fig. 2c),
whereas the expression was already maximal after one week
(Fig. 2d). The apical-to-basolateral transport flux (correlated to
the paracellular transport route) has been quantified by
measuring the permeability of the epithelial monolayer to
fluorescein isothiocyanate (FITC)-4 kDa dextran (Fig. 2e). IL-6
was selected as the primary measure in our experiments.
Nevertheless, the final selection of the inflammation marker to
be monitored will depend on the results of the running human
trial. Other biomarker candidates are tumor necrosis alpha
(TNFa) and interleukin-1b (IL-1b). A significant increase of IL-6
secretion was observed in the basolateral media after treating
the apical side of Caco-2 cells with LPS and TNFa for 24 h
(Fig. 2f). Since the Caco-2 intestinal barrier protects macro-
phages from LPS very well, more than a thousand-fold
increased concentration of LPS had to be added on the apical
side to reach a level of pro-inflammatory cytokine production
that is similar to the response induced when LPS is added
basolaterally. No cell de-sensitization was observed after LPS
and TNFa treatment.
Differentiated monocytes (macrophages) were also treated
on-chip with different concentrations of LPS and the secreted
IL-6 was quantified using an immunomagnetic assay. To this
purpose, magnetic beads of 2.8 mm in diameter (Invitrogen,
Switzerland) were conjugated with human IL-6-specific anti-
body (Invitrogen, Switzerland) and mixed with the supernatant
of the stimulated cells to capture the released IL-6.
Phycoerythrin-conjugated detection antibody against IL-6
(BioSciences, Switzerland) was then introduced to complete
the sandwich immunoassay under magnetic trapping of the
beads. After washing, the fluorescence intensity due to the
phycoerythrin-conjugated detection antibody was measured
using a fluorescent microscope and analyzed using ImageJ
software (see Fig. 2g). Our preliminary results show a
significant increase of the IL-6 concentration after treating
the macrophages with LPS, which demonstrates the possibility
of quantifying the induced cytokines using an on-chip
immunomagnetic assay. Also, a human intervention study is
being conducted to validate the in vitro co-culture model
system for measuring the pro-inflammatory activity of a high-
fat meal, followed by comparison with the effect of the
application of anti-inflammatory dairy products.
Fluorescence detection and imaging system
Microfluidics and optical detection have been shown to be
matched due to the non-invasive nature of optical measurement
techniques and the transparency of the microfluidic fabrication
materials (e.g. glass and PDMS). The Nutrichip platform will
also encompass a dedicated fluorescence camera and image
processing system. The fluorescence intensity correlated to the
captured cytokines on the surface of magnetic beads will be
acquired by a dedicated complementary metal oxide semicon-
ductor (CMOS) imager. The CMOS imaging sensor is made
using a conventional CMOS semiconductor manufacturing
process. Several transistors next to each photosensor convert
the light energy to a voltage. Additional circuitry on the chip
may be included to convert the voltage to digital data. These
imaging sensors have gained popularity recently as powerful
and low-cost devices for cell imaging applications. A special
CMOS design will reduce the imager noise while decreasing the
pixel area of the sensors. This approach enables an image
quality comparable with state-of-the-art charge coupled device
(CCD) cameras.30 The ‘‘smart’’ aspect of the NutriChip imager
lies on the interpretation of the collective information gathered
by the output of the imaging system. This task will be carried
out by a dedicated image-processing unit, which will enhance
the quality and the detection sensitivity thanks to the target sub-
resolution and generation of synthetic images of fluorescently
stained cells.31 The related algorithms will be implemented in a
Digital Signal Processor or Field Programmable Gate Array
Integrated Circuit in order to have on-line image processing and
data analysis. Therefore, the final optical detection system will
combine a CMOS imager and a CMOS processing unit for real-
time quantitative analysis.
As we have seen before, an increased concentration of LPS
induces pro-inflammatory cytokine. Bogunovic et al.32 showed
that the Toll-like Receptor 2 (TLR2) is found by in vitro immuno-
fluorescence staining of intestinal cells. Moreover, Chen et al.33
demonstrated that LPS, in addition to its classical receptor
TLR4, induces the expression of TLR2 in intestinal cells and
that TLRs appears to be important for regulating the intestinal
epithelial barrier integrity by regulating the expression of
proteins involved in TJs. In our preliminary studies, we
confirmed similar findings by inducing TLR2 expression on
Caco-2 cells treated with LPS. Therefore, the ultimate goal of our
fluorescence detection and imaging system is to provide
imaging and quantitative analysis of both cytokine and
expressed TLRs, including TLR2. In both cases, fluorescent
staining using specific antibodies provides imaging of the
biomarkers. For example, Fig. 3a shows TLR2 induced by LPS
on Caco-2 cells. These images are acquired in the NutriChip
system in order to get an on-line quantitative estimation of the
TLR2 receptors. In analogy, images like the one shown in Fig. 3b
are acquired using fluorescent microbeads in order to obtain an
on-line quantitative estimation on pro-inflammatory cytokines.
Future: nutrikinetic studies
Intestinal calcium absorption is an important process that is
involved in the maintenance of calcium hemostasis.34 Calcium
is absorbed in mammals along two routes: using a transcel-
lular mechanism, predominantly taking place in the duode-
num and a passive paracellular mechanism, where the
concentration is dependent on the diffusional processes. The
importance of pharmacokinetics has long been recognized in
medicine and pharmacology and ADME studies are essential
components for the development of efficient and safe drugs.
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In nutrition research, the concept of nutrikinetics is still in its
infancy, but will undoubtedly become more important in the
future. Monitoring the bio-availability of nutrients in digested
food is an extremely important task in nutrition research,
which aims at quantifying the contribution of a certain type of
food as a source of a specific nutrient (e.g., calcium). The
NutriChip platform will also be used for investigating the bio-
availability of calcium by quantitatively monitoring the
adsorption and transport of calcium through the epithelial
cell layer, as well as calcium uptake by target cells. The Caco-2
cell layer again serves here as a model for the intestinal barrier
through which calcium transport will take place.35 The
NutriChip platform has the potential to significantly improve
nutrikinetic measurements and alleviate some of the restric-
tions of classical in vitro systems for monitoring the bio-
availability of calcium, by a combination of both microfluidic-
based cell culture and manipulation with time-resolved
fluorescent imaging. The setup for detecting the bio-avail-
ability of calcium includes a dedicated imaging setup, which
relies on the ratio imaging technique and quantification of the
fluorescent emission intensities of specific dyes, which change
their absorbance spectra upon binding to Ca2+. Several
fluorescent probes show a spectral response upon binding
Ca2+, which enabled researchers to investigate changes in
transport and absorption of Ca2+ using fluorescent micro-
scopy, flow cytometery and fluorescent spectroscopy. Fura-2 is
the most popular dye for ratio-imaging microscopy; it is an UV-
excited Ca2+ indicator that undergoes a shift in absorption
upon binding to Ca2+.36 Our system will be used for detecting
both free transported Ca2+ through the epithelial monolayer as
well as the intracellular Ca2+ absorbed by the target cells. The
system will be interfaced by a fluidic injection unit for
continuous flow media exchange and will contain a magnetic
washing, purification and separation module.
An integrated platform as a paradigm for
nutrient analysis
The NutriChip platform will be a first-generation integrated
system centered on the miniaturized GIT. After establishing
the biologically immune competent GIT model, the miniatur-
ized GIT, and the imaging unit, we will turn our attention to
integrate these components in a modular system, which allows
the application od continuous liquid flows that mimic the in
vivo environment of the human GIT. The size of the
miniaturized GIT device would allow for the integration of
an array of identical units, which can be addressed either with
the same or different epithelium regulators or immune cell
stimuli for high-throughput screening and analysis of several
nutrients for faster and efficient prediction of the influence of
food ingestion. In the future, the system can be further
expanded to include an on-chip digestion functionality.
Despite the intrinsic potential of microfluidic devices, accom-
modating new analysis and protocols into a micro-scale
environment will require the tackling and solving of practical
challenges, particularly those associated with the analysis of
complex samples, such as food.37 Additionally, integrating
sample treatments, such as food digestion, co-culture of
different types of cells and/or bacteria, immunoassays, etc,
would involve designing a microfluidic network capable of
manipulating the involved fluidic samples where and when
desired. We believe that the prototypical NutriChip platform
will be able to clearly demonstrate a new technology paradigm,
and is generic enough to open other applications in the food
technology area, or for the analysis of other types of food.
References
1 A. N. Margioris, Curr. Opin. Clin. Nutr. Metab. Care, 2006,
12, 129–137.
2 F. Nappo, K. Esposito, M. Cioffi, G. Giugliano, A.
M. Molinari, G. Paolisso, R. Marfella and D. Giugliano, J.
Am. Coll. Cardiol., 2009, 39, 1145–1150.
3 G. Verge`res, B. Bogicevic, C. Buri, S. Carrara, M. Chollet,
L. Corbino-Giunta, L. Egger, D. Gille, K. Kopf-Bolanz,
K. Laederach, R. Portmann, Q. Ramadan, J. Ramsden,
F. Schwander, P. Silacci, B. Walther and M. Gijs, Br. J. Nutr.,
2012, 142, 245–250.
4 Z. F. Bhat and H. Bhat, Int. J. Dairy Sci., 2011, 6, 1–12.
5 D. B. Panagiotakos, C. H. Pitsavos, A. D. Zampelas, C.
A. Chrysohoou and C. I. Stefanadis, J. Am. Coll. Nutr., 2010,
29, 357–364.
Fig. 3 (a) Fluorescent image of TLR2, as induced by application of LPS, acquired on Caco-2 cells. (b) Fluorescent image of a test sample of fluorescent micro-beads of 6
mm diameter using excitation/emission wavelengths of 505/515 nm.
202 | Lab Chip, 2013, 13, 196–203 This journal is  The Royal Society of Chemistry 2013
Focus Lab on a Chip
Pu
bl
ish
ed
 o
n 
27
 N
ov
em
be
r 2
01
2.
 D
ow
nl
oa
de
d 
by
 E
CO
LE
 P
O
LY
TE
CH
N
IC
 F
ED
 D
E 
LA
U
SA
N
N
E 
on
 1
0/
02
/2
01
4 
11
:2
6:
21
. 
View Article Online
6 D. C. Hunter, R. Brown, T. Green, C. Thomson, M. Skeaff,
S. Williams, J. M. Todd, C. E. Lister, T. McGhie, J. Zhang,
H. Martin, P. Rippon, R. Stanley and M. A. Skinner, Int. J.
Food Sci. Nutr., 2012, 63, 90–102.
7 P. J. Nestel, S. Pally, G. L. MacIntosh, M. A. Greeve,
S. Middleton, J. Jowett and P. J. Meikle, Eur. J. Clin. Nutr.,
2012, 66, 25–31.
8 M. M. Most, A. G. Ershow and B. A. Clevidence, J. Am. Diet.
Assoc., 2003, 103, 729–735.
9 J. B. Furness, W. A. A. Kunze and N. Clerc, Am. J. Physiol.
Gastrointest. Liver. Physiol., 1999, 277, 922–928.
10 S. Yeruva, G. Ramadori and D. Raddatz, Int. J. Colorectal
Dis., 2008, 23, 305–317.
11 G. Bisping, N. Lugering, S. Lutke-Brintrup, H. G. Pauels,
G. Schurmann, W. Domschke and T. Kucharzik, Clin. Exp.
Immunol., 2001, 123, 15–22.
12 E. L. Ferrec, C. Chesne, P. Artusson, D. Brayden, G. Fabre,
P. Gires, F. Guillou, M. Rousset, W. Rubas and M.
L. Scarino, ATLA, 2001, 29, 649–668.
13 G. Rovera, T. A. O’Brian and L. Diamond, Science, 1979,
204, 868–870.
14 D. Huh, G. A. Hamilton and D. E. Ingber, Trends Cell Biol.,
2011, 21, 745–754.
15 D. Huh, B. D. Matthews, A. Mammoto, M. Montoya-Zavala,
H. Y. Hsin and D. E. Ingber, Science, 2010, 328, 1662–1668.
16 H. J. Kim, D. Huh, G. Hamilton and D. E. Ingber, Lab Chip,
2012, 12, 2165–2174.
17 G. J. Mahler, M. B. Esch, R. P. Glahn and M. L. Shuler,
Biotechnol. Bioeng., 2009, 104, 193–205.
18 J. H. Sung and M. L. Shuler, Lab Chip, 2009, 9, 1385–1394.
19 G. J. Mahlera, M. L. Shulerb and R. P. Glahnc, J. Nutr.
Biochem., 2009, 20, 494–502.
20 J. H. Sung, C. Kama and M. L. Shuler, Lab Chip, 2010, 10,
446–455.
21 J. H. Sung, J. Y. Dan Luo, M. L. Shuler and J. C. March, Lab
Chip, 2011, 11, 389–392.
22 A. S. Sandberg, Int. J. Vitam. Nutr. Res., 2010, 80, 307–313.
23 P. Shah, V. Jogani, T. Bagchi and A. Misra, Biotechnol. Prog.,
2006, 22, 186–198.
24 J. R Kanwar and R. K Kanwar, BMC Immunol., 2009, 10, 7.
25 C. R. H. Raetz, J. Bacteriol., 1993, 175, 5754–5753.
26 M. B. Esch, T. L. King and M. L. Shuler, Annu. Rev. Biomed.
Eng., 2011, 13, 55–72.
27 Q. Ramadan and M. A. M. Gijs, Analyst, 2011, 136,
1157–1166.
28 M. Shimizu, Biosci., Biotechnol., Biochem., 2010, 74,
232–241.
29 J. R. Turner, Adv. Drug Delivery Rev., 2000, 41, 265–281.
30 G. Ko¨klu¨, J. Ghaye, R. Beuchat, G. De Micheli, Y. Leblebici
and S. Carrara, 2012 IEEE International Symposium on
Circuits and Systems (ISCAS), 2012, DOI: 10.1109/
ISCAS.2012.6271688.
31 J. Ghaye, G. De Micheli and S. Carrara, BioNanoScience,
2012, 2, 94–103.
32 M. Bogunovic, S. H. Dave´, J. S. Tilstra, D. T. W. Chang,
N. Harpaz, H. Xiong, L. F. Mayer and S. E. Plevy, Am. J.
Physiol.: Gastrointest. Liver Physiol., 2007, 292,
G1770–G1783.
33 J. Chen, J. N. Rao, T. Zou, L. Liu, B. S. Marasa, L. Xiao,
X. Zeng, D. J. Turner and J. Y. Wang, Am. J. Physiol.:
Gastrointest. Liver Physiol., 2007, 293, G568–76.
34 A. V. Perez, G. Picotto, A. R. Carpentieri, M. A. Rivoira, M.
E. Lopez and N. T. De Talamoni, Digestion, 2008, 77, 22–34.
35 S. Cosentino, C. Gravaghi, E. Donetti, B. M. Donida,
G. Lombardi, M. Bedoni, A. Fiorilli, G. Tettamanti and
A. Ferraretto, J. Nutr. Biochem., 2010, 21, 247–254.
36 G. Grynkiewicz, G. M. Poenie and R. Y. Tsien, Biol. Chem.,
1985, 260, 3440–3450.
37 M. Asensio-Ramos, J. Hernandez-Borges, A. Rocco and
S. Fanali, J. Sep. Sci., 2009, 32, 3764–3800.
This journal is  The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 196–203 | 203
Lab on a Chip Focus
Pu
bl
ish
ed
 o
n 
27
 N
ov
em
be
r 2
01
2.
 D
ow
nl
oa
de
d 
by
 E
CO
LE
 P
O
LY
TE
CH
N
IC
 F
ED
 D
E 
LA
U
SA
N
N
E 
on
 1
0/
02
/2
01
4 
11
:2
6:
21
. 
View Article Online
